typically dose-related and diminishing over time Serious risks : Pancreatitis (rare), gallbladder events, thyroid C-cell tumor boxed warning (from rodent studies) Dose escalation : Slow titration (0.25 mg escalating monthly) mitigates GI tolerability Strength : The safety database is massive, with well-defined risk-benefit profile across multiple patient populations Survodutide Side Effects# Less well-characterized with limited clinical exposure: GI effects : Expected GLP-1 class effects (nausea, vomiting, diarrhea) observed in Phase 2 Glucagon-specific concerns : Potential for hepatic glucose output increase (mitigated by GLP-1 component), theoretical impact on blood glucose in diabetic populations Heart rate : Glucagon receptor agonism may affect heart rate
The bottom line Ozempic and Adderall may both be used off-label for weight loss
PAIS and inflammation The importance of inflammation in PAIS remains a disputed issue for several reasons
Lee JW, Choi H-S, Gyuris J, Brent R, Moore DD (1995) Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor
doi: 10.1186/s12933-018-0708-x 56 SoliniAGianniniLSeghieriMVitoloETaddeiSGhiadoniLet al
Dizziness Feelings of dizziness or lightheadedness have also been reported in some patients
